|
|
 |
|
Viewing report
|
|
|
|
The Europe Biotechnology Sectors : A Company and Industry Analysis (April 2005)
Mergent, April 2005, Pages: 36
This report examines the biotechnology sectors in Europe, specifically the markets of France, Germany, the Netherlands, Sweden, Switzerland and the United Kingdom
Current Environment - Key Points
- The region's biotech regained its momentum and focus in 2004
This was largely driven by a positive flow of product news, stronger revenue growth, and a continuing consolidation wave
- Driven by advantages of efficiently structured healthcare systems and high accessibility of patient recruitment, the European Union's ten new member states offered impressive capacity for conducting clinical trials
- Demand for rapeseed oil to produce biodiesel surged over the past year, as biofuel production capacity rose dramatically thanks to the EU's measures to move toward a bioeconomy
- In early 2005, the EU was urged by the US to reconsider its rejection of genetically modified (GM) crop technology transfer to developing nations, claiming that the risks of growing biotech crops were being gravely overestimated in Europe
- A strategic rationale, rather than simple survival, drove consolidations
The growing number of transatlantic M&A deals implied that US companies were acknowledging the considerable value among European biotechs
- In 2004, 14 European companies made initial public offerings (IPOs), most of them UK-based biotechs
Experts anticipated a continuation of the flow of IPOs in 2005, albeit in an increasingly selective and value-sensitive market
Industry Profile - Key Points
- Within Europe, Germany, the UK, France, Switzerland, the Netherlands and Sweden remain the region's biotech leaders
- In 2004, the number of public and private biosciences companies across the six major European biotech nations was estimated at more than 2,000, compared with around 1,350 in 2003
- Nanotech is set to play a larger role in the region's biotech industry, as Europe is increasingly strengthening R&D in this rapidly growing, multidisciplinary sector that often intersects with bioscience fields
- More focus is being placed on white biotech (or industrial biotech), as it is expected to spearhead the next revolution in manufacturing industries in Europe (and globally), as nations move toward the creation of bio-economies
- In 2004, most of Europe's technology industries attracted more venture capital than in the previous year
Experts stated that biotech and healthcare companies attracted the largest slice of venture capital in 2004, with -1.3 billion (US$1.8 billion) raised, up 29% from 2003
- In late November, the European Commission (EC) put pressure on five EU member states to lift their national bans on GM products
- Upon the request of the EC, the European Food Safety Authority (EFSA) finalized in late November a document on the risk assessment of GM plants and derived food and feed
Market Trends and Outlook - Key Points
- European biotechs are expected to begin exploring emerging markets (particularly India and China) that offer low cost structures along with other potential benefits
- Therapeutic monoclonal antibodies (mAbs) are set to gradually replace conventional therapies (small molecule drugs) in Europe, driven by comparatively higher efficiency, minimal side effects, and long term cost-effectiveness
- The US- restrictions on embryonic stem cell research (since 2001) and its human cloning ban (since 2003) is causing it to gradually lose ground in this field, while opportunities are opening up across parts of Europe
- Progress in 2004 indicated that the industry is heading toward greater profitability, thanks to a general comeback in investor confidence in the sector, recovering national stock markets, and dynamic progress in product development
Customers who bought this item also bought
Biotechnology Reagents - Global Strategic Business Report
Agricultural Biotechnology - Global Strategic Business Report
Probiotics - Global Strategic Business Report
Biotechnology Instrumentation - Global Strategic Business Report
Agricultural Biotechnology - Global Market Trends
Gene Amplification Technologies - Global Strategic Business Report
Marine Biotechnology - Global Strategic Business Report
Polymerase Chain Reaction (PCR): Products/Tools - A Global Market Watch, 2009-2015
Gene Therapy - Global Strategic Business Report
Proteomics - Global Strategic Business Report
|
|
|
|
